Peter Hotez, M.D., Ph.D., president of Sabin, testified this week at two congressional hearings: the House Energy and Commerce Subcommittee on Oversight and Investigations hearing, “Examining the U.S. Public Health Response to the Zika Virus”; and the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on “The Growing Threat of Cholera and Other Diseases in the Middle East.”
Statements and Press Releases
WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.
WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.
WASHINGTON, D.C. – April 25, 2014 – Twenty years ago, the immunization landscape was starkly different from what it is now. More than 100,000 cases of poliomyelitis and 1.2 million cases of measles occurred each year, and few low-income countries outside of the Americas had immunization plans. Neglected tropical diseases (NTDs), which have existed since biblical times, wreaked havoc without recognition due to an absence of coordinated advocacy and government funding.